ILM1: Medios AG - Summary | Jitta

Medios AG

DEU:ILM1

Price
€13.48
Loss Chance
44.6%
4.62JITTA SCORE
55.86%Under Jitta Line
Jitta Ranking
123 / 548
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (46)
Recent Business Performance (49)
Financial Strength (82)
Return to Shareholders (8)
Competitive Advantage (46)
Jitta Signs
Operating MarginConsistent
Cash Conversion CycleLess than 30 days
Revenue and EarningEarning decline from 2022-2025
Recent Business PerformanceEarning decline 20.08% in the last quarter (yoy)
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
4.62
55.86%
4.17
65.16%
Health Care Distributors
2.24
100.00%
2.24
100.00%
COMPANY DESCRIPTION
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and parenteral nutrition solutions. The International Business International covers all activities in the international environment from the procurement of Active Pharmaceutical Ingredients, the sterile and non-sterile drugs and the supply of public and hospital pharmacies through homecare service. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. Medios AG is founded in 2015 and was headquartered in Berlin, Germany.